GCP
CMMB

GSA Capital Partners’s Chemomab Therapeutics CMMB Stock Holding History

GSA Capital Partners’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,819
Closed -$78K – 1472
2021
Q4 		$78K Buy
+2,819
New +$100K 0.01% 1328

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

GSA Capital Partners's CMMB Position: Q1 2022 in Review

GSA Capital Partners sold out of Chemomab Therapeutics (CMMB) in Q1 2022, closing a stake of 2,819 shares — an estimated $78K sold.

GSA Capital Partners first reported a position in CMMB in Q4 2021 and held it in 1 quarter. The position peaked at $78K in Q4 2021. 16 funds tracked by Wall St. Rank hold CMMB as of Q1 2022.

  • GSA Capital Partners reported no remaining Chemomab Therapeutics position as of Q1 2022 after selling out during the quarter.
  • GSA Capital Partners sold 2,819 Chemomab Therapeutics shares in Q1 2022, an estimated $78K.
  • GSA Capital Partners first reported a position in Chemomab Therapeutics in Q4 2021 and held it in 1 quarter.
  • GSA Capital Partners's Chemomab Therapeutics position peaked at $78K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.